---
document_datetime: 2026-01-26 17:20:27
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/avtozma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: avtozma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9137883
conversion_datetime: 2026-01-29 11:40:04.977652
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Avtozma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | This was an application for a group of | 11/12/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000280589   | variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.d Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the active substance - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.f Change outside the approved specifications limits range for the active substance - Accepted B.I.c.1 Change in immediate packaging of the active substance - B.I.c.1.b Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological active substances - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a   |            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000293233 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/12/2025 |

<div style=\"page-break-after: always\"></div>

|                                       | secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |             |                                                                                                                                                                     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000291991 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.c Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.c Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol - Accepted | 04/12/2025 | SmPC and PL | The SmPC sections 6.3 and 6.4 have been updated to reflect the extension of the shelf-life and the revised storage conditions. The PL has been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000314272   | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                       | 27/11/2025   | N/A   |                        |                                                                                                                                                                                                                                                            |
|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000296315      | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted                                                                                                                                                | 01/10/2025   | N/A   |                        |                                                                                                                                                                                                                                                            |
| Variation type IA_IN / EMA/VR/0000297134   | This was an application for a group of variations. B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted | 23/09/2025   |       | SmPC, Labelling and PL |                                                                                                                                                                                                                                                            |
| Variation type IB / EMA/VR/0000287521      | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (Type IB) - To update Section 6.6. of the SmPC and Step 4 of the Instruction for                                                                                                                                                                                                                                | 29/07/2025   |       | SmPC and PL            | To update Section 6.6. of the SmPC and Step 4 of the Instruction for Use (IFU) in the PL for the pre- filled syringe and pre-filled pen of Avtozma 162 mg solution for injection (EU/1/24/1896/007-012) to amend the temperature range from 20°C - 25°C to |

<div style=\"page-break-after: always\"></div>

|                                       | Use (IFU) in the PL for the pre-filled syringe and pre-filled pen of Avtozma 162 mg solution for injection (EU/1/24/1896/007- 012) to amend the temperature range from 20°C - 25°C to 18°C - 28°C based on approved long-term and accelerated stability data. In addition, the MAH took the opportunity to implement an editorial change to Section 4.8 of the SmPC in DE to insert a number, in alignment with the PI in other EU languages, that was previously removed by accident.   |            |     |                        | 18°C - 28°C based on approved long-term and accelerated stability data.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|---------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000284306 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                               | 16/07/2025 | N/A |                        |                                                                           |
| Article 61(3) / EMA/N/0000275336      | - Notification acc. Article 61(3) - Accepted Update of the labelling (annex IIIA) to delete PC, SN and NN from the labelling section of the inner cartons (4P) within the multipack (12P).                                                                                                                                                                                                                                                                                               | 10/07/2025 |     | Labelling              |                                                                           |
| Variation type IB / EMA/VR/0000273930 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological                                                                                                                                                                                                                                                                                              | 19/06/2025 |     | SmPC, Labelling and PL |                                                                           |

<div style=\"page-break-after: always\"></div>

|                                       | medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   |            |     |    |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|-------------------|
| Variation type IB / EMA/VR/0000272244 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                               | 06/06/2025 | N/A |    |                   |
| Variation type IB /                   | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                            | 22/05/2025 | N/A |    | EMA/VR/0000267171 |
| Variation type IB / EMA/VR/0000266466 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted                                                                                                                                                               | 22/05/2025 | N/A |    |                   |
| Article 61(3) / EMA/N/0000255445      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                         | 10/03/2025 |     | PL |                   |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000288251   | - -   | Maintenance   |
|------------------------------|-------|---------------|